Dan is our Executive Vice President of Biologics and Corporate Development. Dan served as Finance Director from 2011 to May 2013, and has held multiple roles at Eagle during his tenure.
Prior to joining Eagle in 2007, Dan held a variety of management positions, such as Senior Analyst at Ethicon (a Johnson & Johnson Company subsidiary) and Lead Finance Liaison throughout Ethicon’s joint venture with Omrix Biopharmaceuticals. Dan additionally held several finance positions at Ranbaxy Pharmaceuticals Inc. (a wholly owned subsidiary of Ranbaxy Inc.), which markets generic products in the US.
Dan holds a BS in business administration from West Virginia University and an MBA from Rutgers University.